MCL1 and lip and oral cavity carcinoma: Our studies with obatoclax (GX15-070), one of the pan-Bcl-2 inhibitors capable of inhibiting Mcl-1, demonstrated a potent single-agent activity against oral cancer cells in vitro and in vivo by inducing a rather non-canonical form of cell death, namely “necroptosis” [57].